CYP2D6*4 allele and breast cancer risk: is there any association?
Clin. transl. oncol. (Print)
; 14(2): 157-159, feb. 2012.
Article
en En
| IBECS
| ID: ibc-126116
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
BACKGROUND:
CYP2D6 is an important cytochrome P450 enzyme. These enzymes catalyse the oxidative biotransformation of about 25% of clinically important drugs as well as the metabolism of numerous environmental chemical carcinogens. The most frequent null allele of CYP2D6 in European populations, CYP2D6*4, has been studied here in order to elucidate whether a relationship exists between this allele and the risk of developing breast cancer in a Spanish population. MATERIALS ANDMETHODS:
Ninety-six breast cancer Spanish patients and one hundred healthy female volunteers were genotyped for the CYP2D6*4 allele using AmpliChip CYP450 Test technology.RESULTS:
Homozygous CYP2D6*4 frequency was significant lower in breast cancer patients than in the control group (OR=0.22, p=0.04). The heterozygous CYP2D6*4 group also displayed lower values in patients than in controls but the difference was not significant (OR=0.698, p=0.28). Therefore, the presence of the CYP2D6*4 allele seems to decrease susceptibility to breast carcinoma in the selected population.CONCLUSIONS:
A possible decreased transformation of procarcinogens by CYP2D6*4 poor metabolisers could result in a protective effect against carcinogens (AU)
Buscar en Google
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Polimorfismo Genético
/
Neoplasias de la Mama
/
Carcinoma Lobular
/
Carcinoma Ductal de Mama
/
Carcinoma Intraductal no Infiltrante
/
Citocromo P-450 CYP2D6
Tipo de estudio:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Aged
/
Female
/
Humans
País/Región como asunto:
Europa
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Año:
2012
Tipo del documento:
Article